Volume 89 Issue 9 | p. 27 | Concentrates
Issue Date: February 28, 2011

Forest Labs To Buy Clinical Data Inc.

Department: Business
Keywords: specialty pharmaceuticals, antidepressant

Looking to acquire new products that will offset declining revenues from drugs facing patent expirations, Forest Laboratories will pay up to $1.2 billion to own the specialty pharmaceutical firm Clinical Data, based in Newton, Mass. In January, FDA approved Clinical Data’s new antidepressant Viibryd (vilazodone), which is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. Forest plans to launch Viibryd in the second half of 2011. According to the company, the drug is patent protected at least until March 2020.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment